Stock Price & Analysis

Based on the technical and fundamental analysis of MYO's recent data, here's a concise assessment:

Technical Analysis

The stock is currently trading at $6.08, showing a -2.72% decline in the regular market session with a slight recovery of +0.25% in post-market trading. The RSI at 49.68 indicates neutral momentum, neither overbought nor oversold.

Recent Developments Recent analyst coverage has been notably positive, with multiple firms maintaining bullish stances:

• Craig-Hallum raised their price target to $9 (December 2024)
• HC Wainwright maintains a $7.5 target
• Ascendiant Capital increased their target to $9

Fibonacci Levels Key support and resistance levels:

• Resistance: R1 at $6.35, R2 at $6.55, R3 at $6.89
• Support: S1 at $5.67, S2 at $5.47, S3 at $5.13
• Pivot: $6.01

Buy/Sell Recommendation Based on the technical setup and strong analyst consensus, MYO appears to be in a favorable position for buying at current levels with multiple price targets suggesting significant upside potential between 43-80%.

Based on the technical analysis and recent market data, MYO stock is expected to reach $8.50-9.00 by end of 2025, representing a potential upside of 40-50% from current price of $6.08. The bullish outlook is supported by Ascendiant Capital's recent price target upgrade to $9.00 and strong preliminary Q2 revenue guidance above estimates. The company's strategic initiatives in expanding market presence and improving operational efficiency could drive further growth momentum.

The S1 support level for MYO Stock is $5.93 ,The R1 resistant level for MYO Stock is $6.38.

As of the end of day on 2025-02-14, the price of MYO Stock was $6.22.

The target price for MYO Stock according to analyst rating is 8.25, with the highest price target at 9.00 and the lowest at 7.50. Analysts have a Strong Buy rating on MYO Stock overall.

The market cap of MYO is $209.6M.

Based on the provided data, here's a concise analysis of MYO's valuation:

MYO is currently trading at reasonable valuation levels considering its growth prospects and market position. The stock's PS ratio of 5.86 in Q3 2024 shows a moderate increase from previous quarters, indicating growing market confidence. The PB ratio of 13.05 suggests the market is pricing in future growth potential, though this is higher than ideal for value investors.

Recent analyst consensus strongly supports MYO's growth trajectory, with multiple firms maintaining "Strong Buy" ratings and price targets ranging from $7 to $9, suggesting significant upside potential from current levels around $6.20. Craig-Hallum's recent price target increase to $9 reflects confidence in the company's $17.3M capital raise being effectively deployed for growth initiatives.

The current price of $6.20 represents a reasonable entry point given the strong analyst backing and planned business expansion through advertising and manufacturing capacity investments.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteran’s administration, and others.

Based on the available data and market analysis, here are the price predictions for MYO stock by 2030:

MYO stock is projected to reach $15-18 by 2030, driven by the company's strong revenue growth trajectory and expanding medical device market presence. The recent analyst coverage from Ascendiant Capital raising the price target from $8.5 to $9 indicates positive market sentiment and growth potential. The company's preliminary Q2 2024 revenue guidance above estimates and 20% stock price increase demonstrates improving business fundamentals that support long-term growth.

MYO has a total of 101 employees.